Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription
Authors
Keywords
Phragmunis A, MCL1, FBXW7, ELK1, SRF
Journal
NEUROCHEMISTRY INTERNATIONAL
Volume 147, Issue -, Pages 105051
Publisher
Elsevier BV
Online
2021-05-10
DOI
10.1016/j.neuint.2021.105051
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting Hedgehog signaling pathway: paving the road for cancer therapy
- (2019) Ioana Berindan-Neagoe et al. PHARMACOLOGICAL RESEARCH
- Overview of the Anticancer Profile of Avenanthramides from Oat
- (2019) Eleonora Turrini et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Therapeutic potential of natural products in glioblastoma treatment: targeting key glioblastoma signaling pathways and epigenetic alterations
- (2019) M. N. Abbas et al. Clinical & Translational Oncology
- Current Challenges and Opportunities in Treating Glioblastoma
- (2018) Andrea Shergalis et al. PHARMACOLOGICAL REVIEWS
- Novel therapies hijack the blood–brain barrier to eradicate glioblastoma cancer stem cells
- (2018) Raghupathy Vengoji et al. CARCINOGENESIS
- Adult Glioblastoma
- (2017) Brian M. Alexander et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry
- (2017) Birthe Krogh Rasmussen et al. JOURNAL OF NEURO-ONCOLOGY
- The value of pyrans as anticancer scaffolds in medicinal chemistry
- (2017) Dinesh Kumar et al. RSC Advances
- Problems of glioblastoma multiforme drug resistance
- (2016) A. A. Stavrovskaya et al. BIOCHEMISTRY-MOSCOW
- Mcl-1 inhibitors: a patent review
- (2016) Lijia Chen et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- TAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cells
- (2015) Tian Tian et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Bcl-2 family member Mcl-1 expression is reduced under hypoxia by the E3 ligase FBW7 contributing to BNIP3 induced cell death in glioma cells
- (2015) Yongqiang Chen et al. CANCER BIOLOGY & THERAPY
- Curcumin: A Natural Lead for Potential New Drug Candidates
- (2015) Ana Oliveira et al. CURRENT MEDICINAL CHEMISTRY
- Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis
- (2015) YANG ZHANG et al. ONCOLOGY REPORTS
- Understanding cancer and the anticancer activities of naphthoquinones – a review
- (2015) Kevin W. Wellington RSC Advances
- Bak and Mcl-1 are essential for Temozolomide induced cell death in human glioma
- (2015) Catherine Gratas et al. Oncotarget
- The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
- (2014) Mira Patel et al. Cancers
- The PI3 kinase inhibitor NVP-BKM120 induces GSK3/FBXW7-dependent Mcl-1 degradation, contributing to induction of apoptosis and enhancement of TRAIL-induced apoptosis
- (2013) Hui Ren et al. CANCER LETTERS
- MiR-139 Inhibits Mcl-1 Expression and Potentiates TMZ-Induced Apoptosis in Glioma
- (2013) Rui-Yan Li et al. CNS Neuroscience & Therapeutics
- Evidence for the Natural Toxins from the Mushroom Trogia venenata as a Cause of Sudden Unexpected Death in Yunnan Province, China
- (2012) Zhong-Yu Zhou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Progresses in TCM Metal-Based Antitumour Agents
- (2012) Zhen-Feng Chen et al. Anti-Cancer Agents in Medicinal Chemistry
- Targeting the Bcl-2 family for cancer therapy
- (2012) Shibu Thomas et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Trogia venenata (Agaricales), a novel poisonous species which has caused hundreds of deaths in southwestern China
- (2012) Zhu L. Yang et al. MYCOLOGICAL PROGRESS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now